Imagine calling T-cells, macrophages, and antibodies into action by taking a simple pill that instantaneously programs both adaptive and innate arms of the immune system to attack a tumor or virus, preventing infection and halting disease. Such an approach could meet major unmet challenges in biomedical research and therapy. My goal is to develop novel approaches that allow innate and acquired immunity to be purposefully targeted to pathogens of interest. These studies build on recently revealed mechanisms of Toll-like receptor signaling, ideas concerning approaches of targeting their sensing abilities to pathogens of defined interest and insights gained from our own invention of chemically programmed antibodies. Ultimately, these studies will allow scientists to program a variety of immune cells and responses to attack pathogens of interest using a variety of mechanisms. We will apply these results to studies in cancer therapy. Furthermore, we will explore novel approaches that should allow for circulating immunoglobulins induced with covalent vaccines to be programmed to inhibit HIV-1 and flu virus entry. The vaccines that result from these studies may be of both prophylactic and therapeutics utility. I will develop novel chemical approaches aimed at learning how to purposefully target innate immunity, T- cells, and macrophages to defined pathogens. I will apply these developments to create new cancer therapies. I will develop a novel approach to orally available chemically programmed immunity. I will apply developments in orally available chemically programmed immunity towards new vaccine strategies for HIV-1 and flu.
This research will explore new approaches towards directing immune responses to fight cancers and viruses. If successful, new therapies for cancer and HIV-1 will result. Additionally, a new approach to vaccines against HIV-1 and swine flu will be created.
|Nagano, Masanobu; Carrillo, Nancy; Otsubo, Nobumasa et al. (2017) In vivo programming of endogenous antibodies via oral administration of adaptor ligands. Bioorg Med Chem 25:5952-5961|
|Perdigão, Pedro; Gaj, Thomas; Santa-Marta, Mariana et al. (2016) Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors. PLoS One 11:e0150037|
|Patterson, James T; Wilson, Henry D; Asano, Shigehiro et al. (2016) Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation. Bioconjug Chem 27:2271-2275|
|Inokuma, Tsubasa; Fuller, Roberta P; Barbas 3rd, Carlos F (2015) N-Sulfonyl-?-lactam hapten as an effective labeling reagent for aldolase mAb. Bioorg Med Chem Lett 25:1684-1687|
|Gaj, Thomas; Liu, Jia (2015) Direct protein delivery to mammalian cells using cell-permeable Cys2-His2 zinc-finger domains. J Vis Exp :|
|Liu, Jia; Gaj, Thomas; Wallen, Mark C et al. (2015) Improved cell-penetrating zinc-finger nuclease proteins for precision genome engineering. Mol Ther Nucleic Acids 4:e232|
|Liu, Jia; Gaj, Thomas; Yang, Yifeng et al. (2015) Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells. Nat Protoc 10:1842-59|
|Wallen, Mark C; Gaj, Thomas; Barbas 3rd, Carlos F (2015) Redesigning Recombinase Specificity for Safe Harbor Sites in the Human Genome. PLoS One 10:e0139123|
|Gaj, Thomas; Barbas 3rd, Carlos F (2014) Genome engineering with custom recombinases. Methods Enzymol 546:79-91|
|Sirk, Shannon J; Gaj, Thomas; Jonsson, Andreas et al. (2014) Expanding the zinc-finger recombinase repertoire: directed evolution and mutational analysis of serine recombinase specificity determinants. Nucleic Acids Res 42:4755-66|
Showing the most recent 10 out of 25 publications